CD39/CD73/A2AR pathway and cancer immunotherapy.

Xia C, Yin S, To KKW, Fu L. · 2023

Read CD39/CD73/A2AR pathway and cancer immunotherapy. by Xia C, Yin S, To KKW, Fu L. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9979453.txt.

Description

Xia and co-authors review the CD39/CD73/A2AR pathway in cancer immunotherapy. Tumors build a suppressive setting that blunts immune attack. Two surface enzymes, CD39 and CD73, convert ATP into adenosine step by step. Built-up adenosine then signals through its receptors.

The A2A receptor drives strong immune suppression through cAMP signaling. Blocking this pathway could restore antitumor immunity. Antibodies and small-molecule blockers are now in clinical trials. They are tested alone and with anti-PD-1 or anti-PD-L1 drugs. The review covers pathway roles in growth, spread, and drug resistance. It also discusses markers to pick patients for such treatment. The authors frame the pathway as a way around immunotherapy resistance.

Catalog record

CREATORXia C, Yin S, To KKW, Fu L.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE85 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9979453

Browse the full library · About the Tower of Babel